4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Stock Report

Market Cap: US$727.6m

4D Molecular Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Kirn

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage32.53%
CEO tenure13yrs
CEO ownership2.6%
Management average tenure2yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 20

4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity

Summary 4D Molecular Therapeutics, Inc. maintains a Buy rating, driven by advancing 4D-150 gene therapy for Wet-AMD and DME into late-stage pivotal trials. FDMT's 4D-150 demonstrated up to 89% reduction in injection burden and maintained visual acuity over two years, with phase 3 topline data expected in 2027. Strong financial position with $458M cash and milestone payments, supporting operations into 2H 2028 and minimizing near-term dilution risk. Upcoming FDMT catalysts include 2-year SPECTRA DME data [2H 2026] and phase 3 4FRONT topline results [1H and 2H 2027], with global regulatory alignment. Read the full article on Seeking Alpha
Analysis Article • May 11

Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report

Investors in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) had a good week, as its shares rose 7.4% to close at...
Seeking Alpha • Feb 18

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Summary 4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME. Despite market skepticism about gene therapy, 4DMT's solid science, regulatory clarity, and financial stability make it a compelling investment opportunity. Read the full article on Seeking Alpha
Analysis Article • Nov 24

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 04

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Summary 4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent dosing and robust safety profile make it an intriguing investment, especially given 4D's strong cash position. The competitive landscape is fierce, with rivals like AbbVie and Adverum, but 4D-150 could still achieve significant market share if approved. Market sell-off appears overdone; 4D's well-funded position and diverse pipeline offer a compelling contrarian bet for risk-tolerant investors. Read the full article on Seeking Alpha
Analysis Article • Aug 10

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jul 19

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Summary A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025. Results from the phase 2 SPECTRA study, using the same gene therapy 4D-150 for the treatment of patients with diabetic macular edema, expected in Q4 of 2024. The global diabetic macular edema market is expected to reach $3.93 billion by 2029. 1E15 vg dose of 4D-710 cleared for dose expansion portion of phase 2 AEROW study; Updated interim data expected in mid-2025. Read the full article on Seeking Alpha
Seeking Alpha • Apr 29

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Summary 4D Molecular Therapeutics is a biotechnology company that develops genetic medicines using its Therapeutic Vector Evolution platform. The company's pipeline includes promising ophthalmology, pulmonology, and cardiology candidates, with Phase 3 progress for wet AMD and cystic fibrosis treatments. FDMT's platform allows for quickly creating custom viral vectors tailored to specific diseases, setting it apart from competitors. FDMT's recent public offering bolsters its position and extends its cash runway to 5.8 years, allowing time for research and clinical trials. I believe FDMT stock is a strong buy, driven by its innovative platform and a robust pipeline with a solid cash position. Read the full article on Seeking Alpha
Seeking Alpha • Feb 06

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Summary 4D Molecular Therapeutics' gene therapy, 4D-150, shows potential to reduce the treatment burden for patients with severe wet AMD. Interim findings from a Phase 2 trial demonstrate up to an 89% reduction in yearly anti-VEGF injections with 4D-150. FDMT plans to initiate a Phase 3 trial in wet AMD in Q1 2025, positioning 4D-150 as a promising candidate in the treatment landscape. Read the full article on Seeking Alpha
Seeking Alpha • Jan 25

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Summary Interim phase 1 data update using 4D-710 for the treatment of patients with Cystic Fibrosis expected in mid-2024. Program update on advancement of 4D-710 into pivotal study either alone or in combination with CFTR modular expected in Q1 of 2024. The global cystic fibrosis market is expected to reach $37.04 billion by 2030. The proprietary Therapeutic Vector Evolution platform has the ability to enhance transgene expression and allow for the ability to overcome limitations observed in prior AAV gene therapies. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has David Kirn's remuneration changed compared to 4D Molecular Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-US$179m

Mar 31 2026n/an/a

-US$161m

Dec 31 2025US$2mUS$667k

-US$140m

Sep 30 2025n/an/a

-US$209m

Jun 30 2025n/an/a

-US$196m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$1mUS$663k

-US$161m

Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Compensation vs Market: David's total compensation ($USD2.05M) is below average for companies of similar size in the US market ($USD3.54M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Kirn (64 yo)

13yrs
Tenure
US$2,051,343
Compensation

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc. He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013 and serve...

Leadership Team

NamePositionTenureCompensationOwnership
John Milligan
Executive Chairman6.1yrsUS$255.00k0.18%
$ 1.3m
David Kirn
Co-Founder13yrsUS$2.05m2.58%
$ 18.8m
Kristian Humer
CFO and Principal Financial & Accounting Officerless than a yearUS$3.99mno data
Fariborz Kamal
Chief Technical Advisorless than a yearUS$1.44m0.011%
$ 78.3k
Theresa Janke
Co-Founder & Chief of Staff13.7yrsUS$2.70mno data
Julian Pei
Head of Investor Relations & Corporate Financeno datano datano data
Katy Barglow
Chief Technical Officerless than a yearno datano data
Scott Bizily
Chief Legal Officer & Corporate Secretary5yrsno data0.016%
$ 113.5k
An Song
Chief Translational Medicine Advisor1.7yrsno datano data
Noriyuki Kasahara
Chief Scientific Advisorno dataUS$488.91kno data
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno datano datano data
Christopher Simms
Chief Commercial & Business Officer2yrsno datano data
2.0yrs
Average Tenure
63yo
Average Age

Experienced Management: FDMT's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Milligan
Executive Chairman6.1yrsUS$255.00k0.18%
$ 1.3m
David Kirn
Co-Founder13yrsUS$2.05m2.58%
$ 18.8m
Charles Theuer
Independent Director10.8yrsUS$135.00k0.075%
$ 548.9k
Susannah Gray
Independent Director6.2yrsUS$135.00k0%
$ 0
Paul Utz
Member of Scientific Advisory Board2.8yrsno datano data
Richard Moss
Member of Scientific Advisory Board2.8yrsno datano data
Jacob Chacko
Independent Director7.5yrsUS$135.00k0%
$ 0
Shawn Tomasello
Independent Director5.8yrsUS$132.50k0%
$ 0
Amit Gaggar
Member of Scientific Advisory Board2.8yrsno datano data
Nancy Miller-Rich
Independent Director5.8yrsUS$122.50k0%
$ 0
Arshad Khanani
Chair of Retina Advisory Board2.1yrsno datano data
Amy Rosenberg
Member of Scientific Advisory Board2.8yrsno datano data
5.8yrs
Average Tenure
64.5yo
Average Age

Experienced Board: FDMT's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 19:06
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

4D Molecular Therapeutics, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Eliana MerleBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research